close Trading birgt Risiken Investieren birgt Risiken und ist nicht für alle Anleger geeignet. CFDs sind komplexe Instrumente und gehen wegen der Hebelwirkung mit dem hohen Risiko einher, schnell Geld zu verlieren.
SuchenSuchen
Change languageDeutsch
Dashboard

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Home・Aktien・REVOLUTION Medicines Inc
Search

REVOLUTION Medicines Inc

Geschlossen

BrancheGesundheitswesen

38.43 3.39

Starkes Kaufsignal

Kursupdate 5. Aug. 2025, 19:59 UTC

BuySell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

36.45

Max

38.59

Schlüsselkennzahlen

By Trading Economics

Einkommen

-19M

-213M

EPS

-1.13

Gewinnspanne

-74.379

Angestellte

616

EBITDA

-24M

-237M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+83.48% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-644M

6.9B

Vorheriger Eröffnungskurs

35.04

Vorheriger Schlusskurs

38.43

Nachrichtenstimmung

By Acuity

50%

50%

175 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

40.67 / 41.96 Unterstützung & Widerstand

REVOLUTION Medicines Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Aug. 2025, 21:42 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

DJ

Lesen

4. Aug. 2025, 21:21 UTC

Ergebnisse
Wichtige Markttreiber

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

DJ

Lesen

4. Aug. 2025, 20:45 UTC

Ergebnisse

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

DJ

Lesen

4. Aug. 2025, 19:15 UTC

Wichtige Markttreiber

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

DJ

Lesen

4. Aug. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lesen

4. Aug. 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

DJ

Lesen

4. Aug. 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Lesen

4. Aug. 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

DJ

Lesen

4. Aug. 2025, 21:30 UTC

Ergebnisse

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

DJ

Lesen

4. Aug. 2025, 21:21 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

DJ

Lesen

4. Aug. 2025, 21:18 UTC

Ergebnisse

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

DJ

Lesen

4. Aug. 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

DJ

Lesen

4. Aug. 2025, 20:25 UTC

Ergebnisse

Transocean 2Q Loss $938M >RIG

DJ

Lesen

4. Aug. 2025, 20:25 UTC

Ergebnisse

Transocean 2Q Loss/Shr $1.06 >RIG

DJ

Lesen

4. Aug. 2025, 20:18 UTC

Ergebnisse

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

DJ

Lesen

4. Aug. 2025, 20:15 UTC

Ergebnisse

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

DJ

Lesen

4. Aug. 2025, 20:14 UTC

Ergebnisse

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

DJ

Lesen

4. Aug. 2025, 20:14 UTC

Ergebnisse

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

DJ

Lesen

4. Aug. 2025, 20:14 UTC

Ergebnisse

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

DJ

Lesen

4. Aug. 2025, 20:13 UTC

Ergebnisse

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

DJ

Lesen

4. Aug. 2025, 20:09 UTC

Ergebnisse

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

DJ

Lesen

4. Aug. 2025, 20:06 UTC

Ergebnisse

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

DJ

Lesen

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

DJ

Lesen

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

DJ

Lesen

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

DJ

Lesen

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

DJ

Lesen

4. Aug. 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

DJ

Lesen

4. Aug. 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

DJ

Lesen

4. Aug. 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

DJ

Lesen

4. Aug. 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

DJ

Lesen

Peer-Vergleich

Kursveränderung

REVOLUTION Medicines Inc Prognose

Kursziel

By TipRanks

83.48% Vorteil

12-Monats-Prognose

Durchschnitt 67.21 USD  83.48%

Hoch 80 USD

Tief 37.91 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für REVOLUTION Medicines Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

10

Buy

0

Halten

0

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für REVOLUTION Medicines Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

40.67 / 41.96Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Recent bullish events outweigh bearish events.

Mittelfristig

Strong Bullish Evidence

Recent bullish events outweigh bearish events.

Langfristig

Bearish Evidence

Recent bearish events outweigh bullish events.

Stimmung

By Acuity

175 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Andere Aktien aus dem Sektor

JNJ

Johnson and Johnson

170.73

↓-0.23%

NVS

Novartis AG

117.78

↓-0.02%

ABT

Abbott Laboratories

130.77

↑ +0.52%

TMO

Thermo Fisher Scientific Inc

466.56

↓-0.22%

ISRG

Intuitive Surgical Inc

476.87

↓-1.3%